Aggrastat 50 mcg/ml Solution for Infusion: Overview
Quick summary: Aggrastat 50 mcg/ml solution for infusion contains tirofiban hydrochloride and is used in hospital settings for acute coronary syndromes. It is given intravenously by healthcare professionals and requires close monitoring for bleeding...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: Aggrastat 50 mcg/ml solution for infusion contains tirofiban hydrochloride and is used in hospital settings for acute coronary syndromes. It is given intravenously by healthcare professionals and requires close monitoring for bleeding and platelet-related effects.
Key point: Dosing, monitoring, and compatibility checks should always follow the official product information and local hospital protocol.
Medical disclaimer: This article is for general information only and is not a substitute for the official leaflet, prescribing information, or advice from a qualified clinician or pharmacist. Aggrastat is a hospital-administered medicine and should only be used under professional supervision.
What is Aggrastat 50 mcg/ml solution for infusion?
Aggrastat is a prescription-only medicine used in the management of acute coronary syndromes, including non-ST elevation acute coronary syndromes (NSTE-ACS). Its active ingredient is tirofiban hydrochloride.
It is given as an intravenous infusion in hospital settings. The medicine works by inhibiting platelet aggregation, which helps reduce the risk of thrombotic cardiovascular events in appropriate patients.
Aggrastat is often used alongside other treatments such as unfractionated heparin and acetylsalicylic acid (ASA), depending on the clinical situation and local protocol.
How is Aggrastat administered?
Aggrastat is administered by healthcare professionals in a controlled hospital environment. It is not a medicine for self-administration.
The usual approach described in the source content is an initial intravenous loading dose followed by a continuous infusion. Patients are monitored closely during treatment to check response and watch for complications.
| Step | Information from the source content |
|---|---|
| Loading dose | 25 mcg/kg IV over 5 minutes |
| Maintenance infusion | 0.15 mcg/kg/min for up to 18 hours |
| Renal impairment | Infusion rate should be halved when creatinine clearance is ≤60 mL/min |
Exact preparation and administration details should always be checked against the product label and local hospital guidance.
What is Aggrastat used for?
Aggrastat is primarily used in the treatment of acute coronary syndromes, especially where there is concern about early myocardial infarction or thrombotic complications.
- Management of non-ST elevation myocardial infarction (NSTEMI)
- Use as part of treatment strategies for patients undergoing percutaneous coronary intervention (PCI)
- Reduction of thrombotic risk in selected acute coronary syndrome patients
Its role is to reduce platelet aggregation during a critical phase of care.
What dosage information is provided in the source content?
The source content describes a weight-based dosing approach. Because this is a hospital medicine, dose calculation and infusion setup should be performed by trained professionals.
- Loading dose: 25 mcg/kg IV over 5 minutes
- Maintenance infusion: 0.15 mcg/kg/min
- Duration: up to 18 hours
- Renal adjustment: reduce the infusion rate in patients with creatinine clearance ≤60 mL/min
If you are checking this medicine for clinical use, confirm the exact regimen in the official product information and local protocol.
What adverse effects are mentioned?
The source content highlights several important adverse effects that require monitoring during treatment.
- Bleeding: including serious bleeding risk, especially when used with anticoagulation therapy
- Thrombocytopenia: a reduction in platelet count
- Hypotension: a drop in blood pressure in some patients
Because these effects can be clinically significant, patients receiving Aggrastat are typically monitored closely in hospital.
What precautions are mentioned?
Several precautions are noted in the source content and are important for safe use.
- Check that the solution is clear and the container is intact before use
- Monitor for signs of bleeding, especially around invasive procedures
- Assess renal function before dosing, since adjustment may be needed
- Use careful monitoring throughout infusion therapy
These precautions help support safe administration in a monitored setting.
What interactions are mentioned?
The source content notes that Aggrastat may interact with other medicines that affect clotting or platelet function.
- Anticoagulants: may increase bleeding risk when used together
- Other antiplatelet drugs: such as ASA, which may require careful monitoring
- IV compatibility issues: the source notes that it should not be mixed with diazepam in the same IV line
Medication reconciliation is important before and during treatment.
Practical points for pharmacists and clinicians
For hospital teams, the key checks are weight-based dose calculation, renal function review, bleeding surveillance, and compatibility with other IV medicines.
It is also important to confirm the exact infusion preparation, line handling, and monitoring requirements from the official leaflet or local protocol.
Frequently asked questions
▸ How do you prepare Aggrastat for infusion?
The source content says the medicine may be supplied as premixed infusion bags or vials. Preparation should follow the manufacturer’s instructions and hospital procedure, with attention to clarity, dilution, and compatibility.
▸ What is the infusion rate for Aggrastat?
The source content states a maintenance infusion of 0.15 mcg/kg/min after the loading dose, with a reduced rate in patients with renal impairment.
▸ What is Aggrastat infusion used for?
It is used in the hospital management of acute coronary syndromes, including NSTEMI, and may be used as part of care around PCI.
▸ What active ingredient does Aggrastat contain?
Aggrastat contains tirofiban hydrochloride.
▸ What should be checked before giving Aggrastat?
The source content highlights checking renal function, bleeding risk, solution integrity, and possible interactions with other medicines.
▸ Are there alternatives mentioned in the source content?
Yes. The source content mentions other glycoprotein IIb/IIIa inhibitors such as eptifibatide and abciximab as alternatives in similar clinical contexts.
Safety reminder
Aggrastat is a high-risk hospital medicine that requires professional preparation, monitoring, and review of the official product information. If you are checking a prescription, infusion chart, or compatibility question, confirm the details with a pharmacist, prescriber, or the current SmPC/leaflet.
Summary
Aggrastat 50 mcg/ml solution for infusion is an intravenous tirofiban hydrochloride product used in acute coronary syndromes. The source content emphasizes weight-based dosing, renal adjustment, bleeding monitoring, and careful attention to interactions and IV compatibility.
For clinical use, always rely on the official product information and local hospital protocol.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.